In the autumn of 1964 a large-scale trial of measles vaccines was begun in Britain under the auspices of the Medical Research Council's Measles Vaccines Committee. The trial was planned to assess the value of the vaccines for general use, and special attention was therefore paid to the degree and frequency of reactions occurring after vaccination and the ability of the vaccines to protect against measles.
visitors at three weeks to assess reactions to vaccination and at three, six, and nine months to record the incidence of measles; additional information on the cases was obtained from the general practitioners.
The results showed that reactions to both schedules of vaccination were generally mild. They also showed that each schedule induced about 85% protection against measles for six months and, furthermore, those vaccinated children who contracted measles had on average a milder attack than those who had the disease in the unvaccinated group.
The findings on the protective effect of the vaccines were based on an analysis of the results of all the children, whereas those on similarity of groups and on reactions to vaccination were from an 11 /,, sample and have since been confirmed by a full analysis for all the children (not reported here).
The trial has now been in progress for two years nine months after vaccination covering the two epidemics of 1964-5 and 1966-7. The results on protection during the whole of these periods have been analysed and are reported here. The analysis has been made in two separate parts-namely, for the first nine months after vaccination (which includes the six months already reported on) and for the subsequent two years (see Chart). There were a number of reasons why this separate analysis was essential. At the end of the nine months, in accordance with a promise made when the trial was initially arranged, measles vaccine was offered to all the unvaccinated children. This offer was accepted for many of the children, who were accordingly excluded from the trial. There still remained, however, a large number of unvaccinated children who had not had measles, and these were included in the follow-up for the subsequent two years. In addition, at the end of the nine months doctor, but there was no evidence of differences in frequency between the three groups (Table III) . (Medical Research Council, 1966) , which were provisional.) The proportions followed up by health visitors in the three groups respectively were 90%, 87%, and 84%. Table II ). Table II ). Follow-up of Ineligible and Defaulter Children As explained in the previous report, a number of children were excluded from the three main groups either because they were ineligible for vaccination on the grounds of health or because they defaulted from vaccination. These children were also followed up. The incidence of measles in the ineligible and defaulter groups during the first nine months was similar to that in the unvaccinated control group (Table IV) . It thus appears unlikely that the necessary exclusion of these children from the three main groups had affected the assessment of the protective effect of the vaccines. (Table IV) or at the end of nine months (Table  V) was not associated with the subsequent incidence of measles.
Protective Effect of Vaccination
The follow-up during the two years was made by postal inquiry. Questionary forms were sent out on two occasions to all the parents of the children in the three trial groups and also Table I , that the proportions of confirmed cases in all three groups were greater, and that the differences between the vaccinated and control groups were less, than those during the nine-months follow-up. This was probably due to an improvement in the arrangements for the rapid confirmation of measles by the doctors. Moreover, those illnesses where the parent was doubtful whether the child had had measles, and the child had not been seen by the doctor, were not included as measles; in the first nine months, however, many such cases were reported as measles by the health visitor and were included among the total cases reported. Table VII ).
It is seen from Table VI that during the two years both schedules of vaccination continued to induce substantial protection against measles. On the basis of confirmed cases the degree of protection for killed/live vaccine was 88% and for live vaccine alone 94% ; the difference between these two figures is significant (at the 0.1% level). A similar significant difference between the protective effect of the two schedules is evident when the degree of protection is calculated from the total number of cases reported by the parents-namely, 87% for the killed/live vaccine and 93% for the live vaccine alone.
A check was made on the occurrence of measles in those children whose parents had not replied to the postal inquiry. A random sample of about 10% of those in each group not answering either inquiry were visited by health visitors. From this sample the number of cases which were seen and confirmed by the doctor were 3 out of 126 visited in the killed/live vaccine group, 1 out of 127 in the live vaccine group, and 37 out of 187 in the unvaccinated group. Though the numbers are relatively small the degrees of protection calculated from the sample, 88% for the killed/live vaccine and 96% for the live vaccine alone, were very similar to those obtained from the main postal inquiry.
With each schedile of vaccination the protective effect may have been even greater than that calculated because the postal follow-up of the unvaccinated group was less complete than that of the two vaccinated groups.
Modification of the Disease by Vaccination
When measles occurred in the vaccinated children it was, as found during the first nine months, generally of a milder form than the disease in unvaccinated children (Table VII) .
Reports were received of a small number of specific complications which occurred in those cases of measles confirmed by the doctor but there was no evidence of significant differences between the three groups (Table VIII) . It is interesting to note, however, that all five cases of convulsions reported were in unvaccinated children. It may also be noted that only one case of encephalitis associated with measles was reported during the whole trial. 
Duration of Protection
A further analysis of the results was made to see whether there was any waning in the degree of protection as the trial progressed. The results for the two-year follow-up were therefore analysed for two separate periods each of a year corresponding to the interepidemic and second epidemic, and compared with those for the first nine months covering the first epidemic (see Chart). Table IX gives the results of the analysis for these three periods of all the cases of measles confirmed by the doctor. For the three consecutive periods the degrees of protection for the killed/live vaccine group were 85%, 86%, and 89% and for the live vaccine group 84%, 91%, and 95%. It is clear that there was no evidence of waning in the protection produced by either of the vaccination schedules as the trial progressed. It was also shown that the live vaccine alone gave a significantly greater degree of protection than the killed/live vaccine during the second period (at the 2 % level) and the third period (at the 0.1% level).
Analysis of AU Confirmed Cases
Because the changes in the study populations at the end of the first nine months may have introduced some small bias in the assessments of the degree of protection from vaccination, it would be unwise to interpret the higher percentages during the second and third periods as evidence of an increase in the degree of protection as the trial proceeded.
Analysis of Cases after Home Contact
A more critical assessment of the degree of protection and its duration was made by analysing the incidence of measles in children known to have been exposed to the disease at home. alone 93%, 97%, and 98%. It is clear that a high degree of protection against measles from home exposure was induced by both schedules and was well maintained as the trial progressed. Again, it was shown that during each of the second and third periods the live vaccine alone gave a significantly greater degree of protection than the killed/live vaccine (both at the 0.1% level).
As with the analysis of all confirmed cases, it would be unwise to suggest an increase in the degree of protection as the trial proceeded.
It should be pointed out that the smaller numbers of children exposed in the home in the unvaccinated group during the second and third periods compared with those in the vaccinated groups was largely a result of the smaller number of children in the unvaccinated group and the less complete response of the parents to the postal inquiry in this group.
Summary and Conclusions
This report gives the results of a controlled trial which was conducted in a number of areas throughout Britain to assess the value of measles vaccines for general use in children. Two immunization schedules were investigated-a single dose of killed vaccine followed a month later by live vaccine, and live vaccine alone.
Both schedules were found to give a high degree of protection against measles. The results, which cover a total follow-up period of two years nine months, have been analysed for three consecutive periods of nine, twelve, and twelve months, the first and last corresponding to measles epidemics. For these three periods respectively, the degrees of protection based on all confirmed cases were 85 %, 86%, and 89% for the killed/live vaccine, and 84%, 91 %, and 95 % for the live vaccine alone. The corresponding figures based on those children known to have been exposed to measles in the home were 93 %, 91 %, and 93% for the killed/live vaccine and 93%, 97%, and 98% for the live vaccine alone. The greater protective effect of the live vaccine alone during the two later periods, compared with the killed/live vaccine, was statistically significant. The results also showed that when measles occurred in vaccinated children it was on average milder than the disease in unvaccinated children.
It may be concluded that there is a strong case for the use of live measles vaccine alone. The previous report (Medical Research Council, 1966) showed that the live vaccine alone was generally acceptable with regard to vaccination reactions. The present report has shown that the live vaccine alone gave a substantial degree of protection which was well maintained throughout the whole period of the trial, which included two epidemics. After the first nine months the live vaccine alone also gave a significantly higher degree of protection than the killed/live vaccine. Further, the use of live vaccine alone has the advantage that only one injection is required. It is desirable, however, that parents should be informed that live vaccine alone sometimes induces a febrile disturbance or a mild measleslike illness which is non-infectious, so as to avoid undue concern if such reactions should occur.
It may be argued that an injection of killed vaccine is of value in reducing the reactions to the subsequent dose of live vaccine. Consideration, however, should also be given to the unusual local and systemic reactions which may sometimes occur when children who have received killed vaccine are exposed to measles or given a dose of live vaccine a number of years later (Fulginiti et at., 1967) . Such reactions, which have been reported entirely from the U.S.A., have so far occurred only in children who have had repeated doses of killed vaccine. They have not been observed in any of the children in the British trial in which only one dose of killed vaccine was given and was followed after a relatively short period of a month by live vaccine. Nevertheless, it would be wise not to use killed vaccine at all until more information is available about the mechanism of such reactions and how they can be avoided.
Though the results so far obtained show that substantial protection was well maintained over a period of almost three years, it is intended to continue the trial to obtain information on the duration of immunity for longer periods. This will indicate whether reinforcing doses should be given and, if so, the most suitable time for their administration.
But though this question of the duration of immunity cannot be answered immediately, it is quite clear from the results so far obtained from this trial that immunization with a single dose of live measles vaccine, if practised on a wide scale throughout Britain, should bring about a striking diminution in the incidence of the disease. Such a reduction has already been achieved in the U.S.A., where extensive vaccination has been in progress on an increasing scale since 1963 (National Communicable Diseases Center, 1967) .
